To ask the Secretary of State for Health and Social Care, whether NHS England has made an assessment of (a) the potential merits of reducing the number of infusions of blood products, (b) improvements in health-related quality of life, (c) improved Haemophilia Joint Health scores and (d) reductions in Annual Bleeding Rates in decision-making on the procurement of haemophilia treatments; and if he will make an assessment of the effectiveness of NHS England’s tendering process for haemophilia treatment.
To ask the Secretary of State for Health and Social Care, what comparative assessment the Government has made of the uptake in England of extended half life treatment for people with (a) haemophilia A and (b) haemophilia B with the uptake of that treatment in (i) Ireland, (ii) Canada and (iii) the EU.
Extended Half Life products are relatively new products for which data is maturing and is collected via the UK Haemophilia database. These products provide an appropriate treatment for some patients.
NHS England, through the Commercial Medicines Unit (CMU), undertakes national tenders which allow all companies who produce plasma, recombinant and extended half-life products to submit prices to be included in the national pricing framework. The relative prices are used to determine commissioning access for all products, including extended half-life products.
Through commissioning processes such as the Haemophilia Quality Dashboard, patient experience of treatment and its outcomes in relation to bleeds and joint scores is kept regularly under review. The opportunity to continuously improve the patient experience and value of treatment with similar or improved clinical outcomes is an area for further assessment based on new and emerging data.
There are a number of new therapeutic agents for haemophilia, including extended half-life products, and many patients are being recruited to clinical trials or early access schemes for new products. When assessing tenders for haemophilia products, NHS England takes into account the clinical outcomes to be achieved, the data available on the products and the prices offered. The aim is to deliver access to a range of treatments to meet individual patient need whilst supporting the use of clinically appropriate lowest cost options to achieve the outcomes required. This process has delivered both access to new treatments and substantial savings. No review of the tendering process is planned.
NHS England regularly reviews its tender framework for blood products to ensure a range of treatments are commissioned to meet individual patient and maximises the use of clinically appropriate lowest cost options to achieve the clinical outcomes required.
An assessment of comparative uptake compared to the uptake in Ireland, Canada and the European Union has not been undertaken.